NASDAQ:CBST

Cubist Pharmaceuticals (CBST) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CBST stock logo

About Cubist Pharmaceuticals Stock (NASDAQ:CBST)

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

CBST Stock News Headlines

Key facts about Cubism
CBST:CA The Cannabist Company Holdings Inc.
His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
What is Cubism?
Cubist Stock Hits New 52-Week High (CBST)
Cubist Rises On Unusually High Volume (CBST)
His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
See More Headlines
Receive CBST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cubist Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/21/2014
Today
4/28/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBST
CUSIP
22967810
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

CBST Stock Analysis - Frequently Asked Questions

How were Cubist Pharmaceuticals' earnings last quarter?

Cubist Pharmaceuticals Inc (NASDAQ:CBST) issued its quarterly earnings data on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.54. The biopharmaceutical company had revenue of $309.20 million for the quarter, compared to the consensus estimate of $305.50 million. The firm's revenue was up 16.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.41 EPS.

What other stocks do shareholders of Cubist Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cubist Pharmaceuticals investors own include Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Netflix (NFLX), Novavax (NVAX), (QIHU) (QIHU), Seagen (SGEN), Bausch Health Companies (BHC), Baidu (BIDU), Booking (BKNG) and BioMarin Pharmaceutical (BMRN).

This page (NASDAQ:CBST) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners